Data Managers Asked . . . |
Question: Should we report biphosphonate therapy as 'planned therapy' on the pre-TED and post-TED forms?
No. We appreciate this question and chance to clarify a reporting decision. During a Tandem CRP/DM conference, it was mentioned that bisphosphonate therapy be included as 'planned therapy' on Form 2450 because some published data suggested that myeloma patients may have had a disease response while only getting bisphosphonate therapy. After further discussion with a broader range of myeloma experts, it was decided that bisphosphonate therapy would not be considered planned therapy.
Question: Shouldn't all molecular and cytogenetic/FISH test results be reported on the post-TED, even if they've always been negative?
No, and here's why. If there wasn't a molecular marker (e.g.,FLT3) or FISH abnormality (e.g.,t(8:21))present at diagnosis or any time prior to the start of prep in an AML patient, then one cannot use these tests to assess the patient's disease post-HCT. One cannot report 'no disease detected' as it is not applicable. Centers should be reporting 'no/not evaluated' in these cases. In order to assess the patient's disease after HCT, something had to be positive at some point. Centers should still obtain molecular markers or FISH/cytogenetics tests as appropriate, even if studies were negative at diagnosis, as the patient could relapse or evolve over time with new abnormalities. |
___________________________________________________________________________________________________
Please keep in touch with CIBMTR Training. We look forward to getting your feedback and comments. Send in general Data Manager questions to CIBMTR Training. You may see your question and its answer in a future "Data Matters" newsletter.
CIBMTR Training
Thank you to the contributors for this month's newsletter: Elizabeth Nista of MUSC Health, Jason Sabo of Taussig Cancer Institute, Nicolette Minas and Kathleen Ruehle of University of Maryland Marlene and Stewart Greenebaum Cancer Center, Mona Ayish of Stanford University School of Medicine, Janet Brunner of CIBMTR.
|